Available evidence doesn?t support screening all pregnant women for vitamin D deficiency, the Committee on Obstetric Practice of the American College of Obstetricians and Gynecologists concludes in an opinion published in Obstetrics and Gynecology (2011;118[1]:197-198).
Available evidence doesn’t support screening all pregnant women for vitamin D deficiency, the Committee on Obstetric Practice of the American College of Obstetricians and Gynecologists concludes in an opinion published in Obstetrics and Gynecology (2011;118[1]:197-198).
The committee recommends considering maternal serum
25-hydroxyvitamin D (25-OH-D) levels in pregnant women suspected to be at increased risk for vitamin D deficiency (ie, vegetarians, women with limited sun exposure, and ethnic minorities, especially those with darker skin) and interpreting the levels in the context of each woman’s clinical situation.
“When vitamin D deficiency is identified during pregnancy, most experts agree that 1,000-2,000 international units (IUs) per day of vitamin D is safe,” the committee writes. “Higher dose regimens used for the treatment of vitamin D deficiency have not been studied during pregnancy,” although most experts concur that as much as 4,000 IU of vitamin D supplementation daily is safe for pregnant and lactating women.
The committee adds that “recommendations concerning routine vitamin D supplementation during pregnancy beyond that contained in a prenatal vitamin should await the completion of ongoing randomized clinical trials.” They also note that insufficient evidence exists to recommend vitamin D supplementation to prevent preterm birth or preeclampsia.
The optimal serum level of 25-OH-D in pregnant women hasn’t been established. A serum level of at least 20 ng/mL (50 nmol/L) is generally considered necessary to prevent bone problems. Some experts have suggested defining vitamin D deficiency as circulating 25-OH-D levels less than 32 ng/mL (80 nmol/L), based on biomarkers of vitamin D activity such as parathyroid hormone, calcium absorption, and bone mineral density.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More